HBV

Hepatitis B virus (HBV) research compounds act on viral replication and on host steps of infection. HBV is a small enveloped DNA virus that copies its genome by reverse transcription of a pregenomic RNA inside the viral nucleocapsid. Nucleoside analogs such as telbivudine are phosphorylated in cells and then interfere with this reverse transcription step. Capsid assembly modulators work elsewhere in the cycle, and heteroaryldihydropyrimidines of the BAY41-4109 racemic type were shown to deplete nucleocapsids, while morphothiadin is a later capsid-directed compound. Virus entry depends on the bile acid transporter sodium taurocholate cotransporting polypeptide (NTCP), identified as the receptor for HBV. Catalpol is an iridoid glycoside listed here for reported activity in HBV cell models.

Items 76-100 of 162

  • 2'-Deoxy-L-adenosine
    Cat. No.
    A50943

    2'-Deoxy-L-adenosine

    2'-Deoxy-L-adenosine is a potent inhibitor of hepatitis B virus (HBV) replication, targeting the viral polymerase with high specificity and selectivity. This compound functions as a synthon for modified oligodeoxyribonucleotides, making it a valuable tool for research focused on HBV and related hepatotropic viruses, including woodchuck and duck hepatitis viruses. Its ability to interfere with viral replication positions it as a significant reagent in studies aimed at understanding and developing therapies for HBV infections.

    10 mg
    $85.00
    25 mg
    $170.00
    All 4 sizes
  • Glycosmisic acid
    Cat. No.
    A50946

    Glycosmisic acid

    Glycosmisic acid is a natural compound that exhibits anti-hepatitis B virus (HBV) activity. It is employed in research related to viral infections, particularly in studies aimed at understanding and developing therapeutic strategies against HBV. This compound may also serve as a valuable tool for investigating the molecular mechanisms underlying HBV pathogenesis.

    1 mg
    $385.00
    5 mg
    $450.00
    All 2 sizes
  • Besifovir Dipivoxil maleate
    Cat. No.
    A50947

    Besifovir Dipivoxil maleate

    Synonyms: LB80380 maleate

    Besifovir Dipivoxil maleate is a potent HBV inhibitor acting as an oral proagent of LB80317. It demonstrates significant efficacy in suppressing hepatitis B virus (HBV) DNA in both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patient populations. This compound is valuable for research into therapeutic strategies for managing chronic hepatitis B infections.

    25 mg
    $1,655.00
    50 mg
    $2,115.00
    All 3 sizes
  • SHR5133
    Cat. No.
    A50948

    SHR5133

    SHR5133 is a potent HBV capsid assembly modulator that functions through the inhibition of hepatitis B virus (HBV) capsid assembly. Demonstrating an EC50 of 26.6 nM, SHR5133 effectively reduces HBV DNA levels. This compound is primarily utilized in research applications focused on HBV infection and therapeutic development.

    25 mg
    $1,800.00
    50 mg
    $2,285.00
    All 3 sizes
  • Firzacorvir
    Cat. No.
    A50949

    Firzacorvir

    Firzacorvir is a cyclic sulfamide compound that targets and modulates the hepatitis B virus (HBV) core protein. It exhibits significant anti-HBV activity with an EC50 of less than 1 μM. This reagent is essential for research applications focused on the treatment and management of HBV infections.

    25 mg
    $1,275.00
    All 1 sizes
  • HBV-IN-46
    Cat. No.
    A50951

    HBV-IN-46

    HBV-IN-46 is a potent inhibitor of Hepatitis B virus (HBV) S-antigen, demonstrating an EC50 value of 2.6 nM. This active metabolite is valuable for research related to HBV infection and presents a promising tool in the development of antiviral therapies targeting HBV. Its specificity and efficacy make it a useful reagent for studying viral replication and host-pathogen interactions in HBV-related research.

    25 mg
    $2,160.00
    50 mg
    $2,770.00
    All 3 sizes
  • HBV-IN-17
    Cat. No.
    A50952

    HBV-IN-17

    HBV-IN-17 is a potent modulator of Hepatitis B Virus (HBV) capsid assembly, exhibiting an effective concentration (EC50) of 511 nM. This compound targets the viral capsid formation, disrupting the assembly process critical for HBV replication. It is useful in research applications focused on understanding HBV biology and developing potential therapeutics for HBV infection.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • HBV-IN-9
    Cat. No.
    A50953

    HBV-IN-9

    HBV-IN-9 is a highly effective inhibitor of HBsAg (HBV Surface Antigen) with an IC50 value of 10 nM. It also demonstrates potent inhibition of HBV DNA production, achieving an IC50 of 0.15 nM in HepG2.2.15 cells. This compound is utilized in research applications focused on hepatitis B virus infection and offers a valuable tool for investigating HBV pathogenesis and therapeutic strategies.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • BA38017
    Cat. No.
    A50955

    BA38017

    BA38017 is a potent modulator of HBV core protein assembly, specifically targeting the hepatitis B virus (HBV) replication process. It demonstrates significant inhibitory activity with an EC50 of 0.20 μM, making it a valuable tool for studying HBV biology. This compound is essential for research applications focused on understanding HBV pathogenesis and evaluating potential therapeutic strategies against hepatitis B infection.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • HBV-IN-43
    Cat. No.
    A50956

    HBV-IN-43

    HBV-IN-43 is a potent inhibitor of Hepatitis B Virus (HBV) replication. This compound demonstrates strong antiviral activity by targeting key viral processes, making it a valuable tool for research into HBV pathogenesis and therapeutic strategies. Its efficacy in inhibiting HBV provides insights into the development of antiviral therapies for Hepatitis B infection.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • Elebsiran
    Cat. No.
    A50957

    Elebsiran

    Synonyms: VIR-2218

    Elebsiran is a small interfering RNA (siRNA) that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. This agent significantly reduces HBV surface antigen (HBsAg) levels and viral load, indicating its potent antiviral activity. By binding to the asialoglycoprotein receptor (ASGPR) on liver cells via the GalNAc ligand, Elebsiran enables liver-targeted delivery while ensuring improved liver safety. This reagent is valuable for research focused on chronic HBV and HDV infections.

    Out of stock

    All 3 sizes
  • HBV Seq1 aa:63-71
    Cat. No.
    A50959

    HBV Seq1 aa:63-71

    HBV Seq1 aa:63-71 is a peptide fragment derived from the hepatitis B virus. This specific sequence is instrumental in studying viral protein structure and function, particularly in the context of immune response and vaccine development. Its application extends to investigations of HBV pathogenesis and potential therapeutic targets within the viral lifecycle.

    Out of stock

    All 3 sizes
  • Ozisiran
    Cat. No.
    A50960

    Ozisiran

    Ozisiran is a small interfering RNA (siRNA) that targets hepatitis B virus (HBV) RNA transcripts, leading to a reduction in viral load. This compound exhibits potent antiviral activity, making it a valuable tool for research into HBV pathogenesis and therapeutic interventions. Its application in studies of antiviral mechanisms can enhance understanding of HBV infection and facilitate the development of novel antiviral strategies.

    Out of stock

    All 3 sizes
  • HBV-IN-41
    Cat. No.
    A50962

    HBV-IN-41

    HBV-IN-41 is a potent inhibitor of the Hepatitis B Virus (HBV), exhibiting a remarkable EC50 of 0.027 μM. This orally active compound effectively targets viral replication, making it a valuable tool for research into HBV pathogenesis and potential therapeutic interventions. Its efficacy positions it as a significant reagent for studies aimed at developing new antiviral strategies against HBV.

    Out of stock

    All 3 sizes
  • Z060228
    Cat. No.
    A50963

    Z060228

    Z060228 is a capsid-targeting anti-HBV agent that inhibits hepatitis B virus (HBV) DNA replication. It demonstrates significant antiviral activity in HepG2.2.15 cell supernatants, making it a valuable tool for HBV research. This compound is useful for studies focused on HBV replication mechanisms and the development of therapeutic strategies against hepatitis B virus infections.

    25 mg
    $1,275.00
    All 1 sizes
  • Valtorcitabine dihydrochloride
    Cat. No.
    A50964

    Valtorcitabine dihydrochloride

    Valtorcitabine dihydrochloride is a prodrug of L-deoxycytidine with targeted activity against hepatitis B virus (HBV). It functions as an HBV inhibitor, effectively reducing viral replication and promoting antiviral responses. This compound is primarily utilized in research focusing on HBV infection and the development of therapeutic strategies for managing viral hepatitis.

    5 mg
    $265.00
    10 mg
    $440.00
    All 5 sizes
  • LPRP-Et-97543
    Cat. No.
    A50965

    LPRP-Et-97543

    LPRP-Et-97543 is a potent anti-HBV agent targeting multiple HBV promoters. It effectively reduces Core, S, and preS promoter activities while exhibiting no impact on the X promoter. This compound is suitable for research into both acute and chronic hepatitis B virus infections, making it a valuable tool for studying viral pathogenesis and potential therapeutic interventions.

    5 mg
    $435.00
    All 1 sizes
  • Junceellolide C
    Cat. No.
    A50966

    Junceellolide C

    Junceellolide C is a transcription inhibitor targeting cccDNA, effectively impeding HBV DNA replication. It demonstrates significant reductions in supernatant HBV RNA, with EC50 values of 5.19 μM and 3.52 μM in HepAD38 cells. This compound is recognized for its potent anti-HBV activity, making it a valuable tool for research into therapeutic strategies against hepatitis B virus infections.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • HBV-IN-31
    Cat. No.
    A50967

    HBV-IN-31

    HBV-IN-31 is a potent inhibitor of covalently closed circular DNA (cccDNA), demonstrating significant anti-HBV activity with an IC50 value of 0.13 µM for hepatitis B surface antigen (HBsAg). This compound effectively impedes cell growth, making it a valuable tool for research applications focused on chronic hepatitis B virus infection and cccDNA-related mechanisms. Researchers may utilize HBV-IN-31 to explore pathways associated with HBV replication and potentially develop therapeutic strategies targeting cccDNA.

    25 mg
    $1,905.00
    50 mg
    $2,445.00
    All 3 sizes
  • HEC72702
    Cat. No.
    A50968

    HEC72702

    HEC72702 is a potent inhibitor of the hepatitis B virus (HBV) capsid, exhibiting an EC50 of 0.039 µM. This compound effectively reduces HBV DNA levels in both plasma and liver tissues in a dose-dependent manner. HEC72702 is primarily utilized in research focused on HBV replication and the development of antiviral strategies against hepatitis B.

    25 mg
    $1,655.00
    50 mg
    $2,115.00
    All 3 sizes
  • AT-61
    Cat. No.
    A50969

    AT-61

    AT-61 is a non-nucleoside inhibitor that targets Hepatitis B virus (HBV) replication. It disrupts the formation of the capsid necessary for pre-genomic RNA, leading to the generation of empty capsids. This compound demonstrates efficacy against drug-resistant HBV mutant strains and is suitable for research focused on HBV infection mechanisms and therapeutic strategies.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • Xalnesiran
    Cat. No.
    A50970

    Xalnesiran

    Xalnesiran is a small interfering RNA (siRNA) specifically designed to inhibit hepatitis B virus (HBV) replication. By targeting and degrading HBV RNA, it plays a crucial role in reducing viral load and the associated liver pathology. Xalnesiran is valuable for research applications focused on chronic hepatitis B treatment strategies and the investigation of RNA interference mechanisms in viral infections.

    Out of stock

    All 3 sizes
  • Glaziovine
    Cat. No.
    A50971

    Glaziovine

    Glaziovine is an antiviral compound derived from Hypserpa nitida, specifically targeting hepatitis B virus (HBV). It demonstrates potent inhibitory activity against HBV, effectively suppressing the secretion of hepatitis B virus surface antigen (HBsAg) in Hep G2.2.15 cells, with an IC50 value of 8 nM. This reagent is valuable for research into antiviral therapies and the mechanisms of HBV infection.

    Out of stock

    All 3 sizes
  • HBV-IN-18
    Cat. No.
    A50972

    HBV-IN-18

    HBV-IN-18 is an HBV capsid assembly modulator (CpAM) that selectively targets the Hepatitis B virus capsid. It demonstrates a biological activity with an EC50 value of 2790 nM, indicating its potential in inhibiting viral assembly. This compound is applicable in research focused on understanding Hepatitis B virus biology and developing antiviral therapies.

    Out of stock

    All 3 sizes
  • Oxynitidine
    Cat. No.
    A50974

    Oxynitidine

    Oxynitidine is an HBV inhibitor that demonstrates potent activity against Hepatitis B virus DNA replication, with an ID50 of 30.8 µg/mL. This compound serves as a valuable tool for investigating viral infections and can be utilized in the development of therapeutic interventions targeting HBV.

    1 mg
    $400.00
    5 mg
    $985.00
    All 2 sizes

Items 76-100 of 162

Added to your cart

View Cart Checkout

    Loading...